Abstract 396P
Background
EAST-LC (JapicCTI-101155) was a randomized phase III trial conducted in East Asia that demonstrated the non-inferiority of oral S-1 to docetaxel (DTX) in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) [H. Nokihara and S. Lu, Annals of Oncology (2017)]. Here, we report the results of elderly pts (EP) subgroup.
Methods
The key inclusion criteria were as follows: age ≥18 years; an ECOG performance status (PS) of 0 to 2; and ≤ 2 previous chemotherapy regimens, including a platinum-based one [if pts had received gefitinib or erlotinib, then three regimens were allowed]. Eligible pts were randomized 1:1 to receive S-1 (80-120 mg/day; days 1-28 in a 6-week cycle) or DTX (60 mg/m2 in Japan, 75 mg/m2 at the other sites; day 1 in a 3-week cycle). EP were defined as aged ≥ 70 years and evaluated the efficacy, safety and quality of life (QOL), using the EORTC QLQ-C30. The primary endpoint of the trial was overall survival (OS).
Results
A total of 190 EP were subjects to this analysis (90 in the S-1 arm and 100 in the DTX arm). There were no significant differences between both arms in terms of baseline characteristics, except for ECOG PS (P = 0.0132). Disease progression was the most common reason for treatment discontinuation in both arms (63.6% and 51.5% in S-1 and DTX arms, respectively), followed by adverse events (AEs) (13.6% and 24.2%). The median OS were 14.7 months versus 12.1 months; HR 0.76 (95% CI: 0.54–1.07) for S-1 versus DTX, respectively. The most common treatment-related AEs were decreased appetite (61.4%), diarrhea (47.7%) and pigmentation (39.8%) in the S-1 arm, and neutropenia (66.7%), alopecia (49.5%) and leukocytopenia (47.5%) in the DTX arm, respectively. The adjusted mean score difference (S-1 – DTX) of EORTC QLQ-C30 global health status until 48 weeks was 7.41 (95% CI: 0.37–14.46).
Conclusions
S-1 was showed the comparable efficacy, safety and QOL to DTX in previously treated EP with advanced NSCLC, and the results were consistent to those of the overall EAST-LC population. These results could support the usage of S-1 as a viable treatment option for EP.
Clinical trial identification
JapicCTI-101155.
Editorial acknowledgement
Legal entity responsible for the study
Taiho Pharmaceutical.
Funding
Taiho Pharmaceutical.
Disclosure
J.C-H. Yang: Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Roche/Genentech; Honoraria (institution), Advisory/Consultancy: Lilly; Honoraria (institution), Advisory/Consultancy: MSD Oncology; Honoraria (institution), Advisory/Consultancy: Merck Serono; Honoraria (institution), Advisory/Consultancy: Celgene; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: Ono Pharmaceutical; Honoraria (institution), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy: Yuhan; Honoraria (institution), Advisory/Consultancy: Hansoh; Honoraria (institution), Advisory/Consultancy: Blueprint Medicines; Honoraria (institution), Advisory/Consultancy: Daiichi Sankyo; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Takeda Oncology; Honoraria (institution), Advisory/Consultancy: Incyte. T.S.K. Mok: Honoraria (self): Taiho; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Officer/Board of Directors: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Clovis Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): SFJ Pharmaceuticals; Shareholder/Stockholder/Stock options, Officer/Board of Directors: Sanomics; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Takeda; Advisory/Consultancy, Officer/Board of Directors: Chi-Med; Honoraria (self), Advisory/Consultancy: ACEA Biosciences; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (self), Advisory/Consultancy: Merck Serono; Research grant/Funding (institution): XCovery; Honoraria (self), Advisory/Consultancy: Ignyta; Honoraria (self), Advisory/Consultancy: ertex Pharmaceuticals. S. Lu: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Hutchison; Research grant/Funding (self): BMS; Research grant/Funding (self): Heng Rui ; Research grant/Funding (self): Beigene; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Roche; Honoraria (self): Hansoh; Honoraria (self): Hengrui Therapeutics; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: MediPharma; Advisory/Consultancy: Simcere; Advisory/Consultancy: ZaiLab; Advisory/Consultancy: GenomiCare; Advisory/Consultancy: Yuhan Corporation; Advisory/Consultancy: PrIME Oncology. K. Nakagawa: Honoraria (self), Research grant/Funding (institution): AstraZeneca K.K.; Honoraria (self), Research grant/Funding (institution): Astellas Pharma Inc.; Honoraria (self), Research grant/Funding (institution): MSD K.K.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Ono Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Novartis Pharma K.K.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer Japan Inc.; Honoraria (self), Advisory/Consultancy: Kyorin Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Bayer Yakuhin, Ltd.; Honoraria (self): Nichi-Iko Pharmaceutical Co., Ltd.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb Company; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly Japan K.K.; Research grant/Funding (institution): Kyowa Hakko Kirin Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Daiichi Sankyo Co., Ltd.; Honoraria (self): Nippon Kayaku Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd.; Honoraria (self), Research grant/Funding (institution): AbbVie Inc. N. Yamamoto: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Ono Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (self), Research grant/Funding (institution): Daiichi Sankyo Company; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda Pharmaceutical Co. Ltd.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (self), Research grant/Funding (institution): Eli Lilly Japan K.K.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Boehringer-Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Pfizer Inc.; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self): Nippon Kayaku; Honoraria (self), Advisory/Consultancy: Merck Biopharma Co., Ltd; Research grant/Funding (self), Research grant/Funding (institution): Astellas Pharma Inc; Research grant/Funding (self), Research grant/Funding (institution): Tsumura & Co.; Research grant/Funding (self), Research grant/Funding (institution): AbbVie GK.; Research grant/Funding (institution): Amgen Inc; Research grant/Funding (institution): Kyorin Pharmaceutical Co., Ltd.; Research grant/Funding (institution): Eisai Co., Ltd. L. Zhang: Research grant/Funding (institution): Roche; Research grant/Funding (institution): BMS; Honoraria (self): MSD; Research grant/Funding (institution): Henrui Pharm. R.A. Soo: Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Honoraria (self): Amgen; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Taiho; Honoraria (self): Takeda; Honoraria (self): Yuhan. S. Morita: Honoraria (self): AstraZeneca K.K.; Honoraria (self): Bristol-Myers Squibb Company; Honoraria (self): Chugai Pharmaceutical Co. Ltd.; Honoraria (self): Eli Lilly Japan K.K; Honoraria (self): MSD K.K.; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim Co. Ltd.; Honoraria (self): Ono Pharmaceutical Co. Ltd.; Honoraria (self): Pfizer Japan Inc.; Honoraria (self): Taiho Pharmaceutical Co. Ltd. T. Tamura: Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self): Chugai; Honoraria (self): Eli Lilly; Honoraria (self): Nippon Kayaku; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Ono; Honoraria (self): MSD; Honoraria (self): Cmic Shift-Zero. All other authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session